Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer.

Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S.

Oncotarget. 2018 Jan 10;9(11):10110-10117. doi: 10.18632/oncotarget.24118. eCollection 2018 Feb 9.

2.

AOAC SMPR 2016.017.

van Breemen R, Betz JM, Evans L, Hall A, Jennens M, Kreider R, Kuszak A, Mudge E, Patel P, Phillips MM, Rimmer CA, Schaneberg BT, Sheshadri A, Solyom AM, Sullivan DM, Szpylka J, Walters DL, White T, Yang J, Young K, Zielinski G, Coates SG.

J AOAC Int. 2017 Jan 1;100(1):294-296. doi: 10.5740/jaoacint.SMPR2016.017. No abstract available.

PMID:
28825562
3.

AOAC SMPR 2016.016.

Carter S, Betz JM, Brown PN, DelFavero J, Dentali SJ, Heersink A, Hendrickson J, Jennens M, Jindal V, Kafley S, Kreider R, Kuszak A, Lawry J, Li W, Mastovska K, Mudge E, Ofitserova M, Patel P, Phillips MM, Phinney CS, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Sullivan JL, Tulk B, Wildman R, Williams J, Wubben JL, Yang J, Young K, Zhou J, Zielinski G, Coates S.

J AOAC Int. 2017 Jan 1;100(1):292-293. doi: 10.5740/jaoacint.SMPR2016.016. No abstract available.

PMID:
28825561
4.

AOAC SMPR 2016.015.

Carter S, Betz JM, Brown PN, DelFavero J, Dentali SJ, Heersink A, Hendrickson J, Jennens M, Jindal V, Kafley S, Kreider R, Kuszak A, Lawry J, Li W, Mastovska K, Mudge E, Ofitserova M, Patel P, Phillips MM, Phinney CS, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Sullivan JL, Tulk B, Wildman R, Williams J, Wubben JL, Yang J, Young K, Zhou J, Zielinski G, Coates S.

J AOAC Int. 2017 Jan 1;100(1):290-291. doi: 10.5740/jaoacint.SMPR2016.015. No abstract available.

PMID:
28825560
5.

AOAC SMPR 2016.014.

Carter S, Betz JM, Brown PN, DelFavero J, Dentali SJ, Heersink A, Hendrickson J, Jennens M, Jindal V, Kafley S, Kreider R, Kuszak A, Lawry J, Li W, Mastovska K, Mudge E, Ofitserova M, Patel P, Phillips MM, Phinney CS, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Sullivan JL, Tulk B, Wildman R, Williams J, Wubben JL, Yang J, Young K, Zhou J, Zielinski G, Coates S.

J AOAC Int. 2017 Jan 1;100(1):288-289. doi: 10.5740/jaoacint.SMPR2016.014. No abstract available.

PMID:
28825559
6.

AOAC SMPR 2016.013.

Carter S, Betz JM, Brown PN, DelFavero J, Dentali SJ, Heersink A, Hendrickson J, Jennens M, Jindal V, Kafley S, Kreider R, Kuszak A, Lawry J, Li W, Mastovska K, Mudge E, Ofitserova M, Patel P, Phillips MM, Phinney CS, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Sullivan JL, Tulk B, Wildman R, Williams J, Wubben JL, Yang J, Young K, Zhou J, Zielinski G, Coates S.

J AOAC Int. 2017 Jan 1;100(1):286-287. doi: 10.5740/jaoacint.SMPR2016.013. No abstract available.

PMID:
28825558
7.

Analysis of Theanine in Tea (Camellia sinensis) Dietary Ingredients and Supplements by High-Performance Liquid Chromatography with Postcolumn Derivatization: Single-Laboratory Validation, First Action 2016.10.

Ofitser M, Nerkar S, Schaneberg BT, Es-Safi NE, Goto T, Jennens M, Johnson HE, Koerner PJ, Marone PA, Phillips MM, Phillips T, Reif K, Solyom AM, Sullivan DM, Torres M, Yang J, Young K, Zhang Y.

J AOAC Int. 2017 Jan 1;100(1):281-284. doi: 10.5740/jaoacint.2016_10. No abstract available.

PMID:
28825557
8.

Determination of Withanolides in Withania somnifera by Liquid Chromatography: Single-Laboratory Validation, First Action 2015.17.

Koshy R, Anand MS, Murali B, Brunelle SL, Sullivan DM, Bzhelyansky A, Es-Safi NE, Ingle P, Phillips T, Sayre C, Rimmer C, Solyom AM, Young K, Zhang Y, Coates SG.

J AOAC Int. 2017 Jan 1;100(1):277-279. doi: 10.5740/jaoacint.2015.17. No abstract available.

PMID:
28825556
9.

AOAC SMPR® 2017.010. Standard Method Performance Requirements (SMPRs) for Identification of Aloe Vera in Dietary Supplements and Dietary Ingredients.

Ingle P, Barrett B, Betz JM, Don C, Es-Safi NE, Griffiths J, Joseph G, Kennedy DC, Mudge E, Phillips MM, Phillips T, Richards LD, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Traub J, Zhang Y, Zielinski G, Coates SG.

J AOAC Int. 2017 Jul 1;100(4):1187-1188. doi: 10.5740/jaoacint.SMPR2017_010. No abstract available.

PMID:
28802313
10.

AOAC SMPR® 2017.009. Standard Method Performance Requirements (SMPRs) for Quantitation of Aloe Vera Characteristic Water-Soluble Main Constituents in Dietary Supplements.

Ingle P, Barrett B, Betz JM, Don C, Es-Safi NE, Griffiths J, Joseph G, Kennedy DC, Mudge E, Phillips MM, Phillips T, Richards LD, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Traub J, Zhang Y, Zielinski G, Coates SG.

J AOAC Int. 2017 Jul 1;100(4):1185-1186. doi: 10.5740/jaoacint.SMPR2017_009. No abstract available.

PMID:
28802312
11.

AOAC SMPR® 2015.016. Standard Method Performance Requirements (SMPRs) for Determination of Vitamin D in Dietary Supplement Finished Products and Ingredients.

Austad J, Barrett B, Betz JM, Burdette CQ, Don C, Erickson A, Griffiths J, Hildreth JB, Ingle P, Jennens M, Ji D, Joseph G, Kennedy DC, Mudge E, Noestheden M, Phillips MM, Phinney CS, Rettinger M, Richards LD, Rimmer CA, Sarma N, Sauza B, Schaneberg BT, Solyom AM, Sullivan DM, Szpylka J, Traub J, Walters DL, Woods JP, Yang J, Yoo SJ, Zhang T, Zhang W, Zhang Y, Zhu J, Zielinski G, Coates SG.

J AOAC Int. 2017 Jul 1;100(4):1182-1184. doi: 10.5740/jaoacint.SMPR2015.016. No abstract available.

PMID:
28802311
12.

AOAC SMPR® 2017.011. Standard Method Performance Requirements (SMPRs) for Identification and Quantitation of Free Alpha Amino Acids in Dietary Ingredients and Supplements.

Zielinski G, Atkinson G, Bhandari SD, Burns P, Citrolo D, Farthing C, Glover B, Horkey A, Johnson HE, Kuszak A, Lin J, Lippert JA, Mudge E, Ofitserova M, Reimann LM, Solyom AM, Sullivan DM, Szpylka J, Travis J, Wubben JL, Yang J, You H, Young K, Coates SG.

J AOAC Int. 2017 Jul 1;100(4):1189-1191. doi: 10.5740/jaoacint.SMPR2017_011. Epub 2017 Jul 21. No abstract available.

PMID:
28730972
13.

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.

Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC.

Oncotarget. 2017 Jun 27;8(26):41827-41840. doi: 10.18632/oncotarget.18103.

14.

Single-shot terahertz time-domain spectroscopy in pulsed high magnetic fields.

Noe GT, Katayama I, Katsutani F, Allred JJ, Horowitz JA, Sullivan DM, Zhang Q, Sekiguchi F, Woods GL, Hoffmann MC, Nojiri H, Takeda J, Kono J.

Opt Express. 2016 Dec 26;24(26):30328-30337. doi: 10.1364/OE.24.030328.

PMID:
28059309
15.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.

Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.

16.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist. 2016 Oct;21(10):1163-1164. Epub 2016 Sep 30.

17.

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM.

J Hematol Oncol. 2016 Aug 24;9(1):73. doi: 10.1186/s13045-016-0304-z.

18.

AOAC SMPR(®) 2016.002.

Paez V, Barrett WB, Deng X, Diaz-Amigo C, Fiedler K, Fuerer C, Hostetler GL, Johnson P, Joseph G, Konings EJM, Lacorn M, Lawry J, Liu H, Marceau E, Mastovska K, Monteroso L, Pan SJ, Parker C, Phillips MM, Popping B, Radcliffe S, Rimmer CA, Roder M, Schreiber A, Sealey-Voyksner J, Shippar J, Siantar DP, Sullivan DM, Sundgaard J, Szpylka J, Turner J, Wirthwine B, Wubben JL, Yadlapalli S, Yang J, Yeung JM, Zweigenbaum J, Coates SG.

J AOAC Int. 2016 Jul;99(4):1122-1124. doi: 10.5740/jaoacint.SMPR2016.002. No abstract available.

PMID:
27455945
19.

AOAC SMPR(®) 2016.001.

Konings EJM, Barrett WB, Beshore M, Beshore T, Buscher J, Crum H, Dave GT, Ebersole BE, Edwards JC, Fink S, Hurley EK, Jayabalan R, Joseph G, Kanaan R, LaBonia SJ, LaGory A, Mohindra D, Neal-Kababick J, Pham T, Phillips MM, Rimmer CA, Sharaf M, Skovbjerg J, Spedding G, Stenerson K, Stryffeler R, Sullivan DM, Szpylka J, Trout D, Yadlapalli S, Yang J, Zhang C, Coates SG.

J AOAC Int. 2016 Jul;99(4):1120-1121. doi: 10.5740/jaoacint.SMPR2016.001. No abstract available.

PMID:
27455944
20.

AOAC SMPR(®) 2016.005.

Ishaq S, Asim A, Betz JM, Bøjstrup M, Cooley J, Dodd LM, Ingle P, Joseph G, Kuszak A, Mudge E, Phinney CS, Reimann LM, Schaneberg BT, Sullivan DM, Szpylka J, Travis J, Walters DL, Young K, Zhou J, Zielinski G, Coates SG.

J AOAC Int. 2016 Jul;99(4):1107-1108. doi: 10.5740/jaoacint.SMPR2016.005. No abstract available.

PMID:
27455941
21.

AOAC SMPR(®) 2016.004.

Myers R, Betz JM, Bøjstrup M, Craft NE, Figore H, Hall A, Joseph G, Kennedy D, Khachik F, Mudge E, Phillips MM, Phillips T, Richards LD, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Szpylka J, Walters DL, White T, Yang J, Zielinski G, Coates SG.

J AOAC Int. 2016 Jul;99(4):1105-1106. doi: 10.5740/jaoacint.SMPR2016.004. No abstract available.

PMID:
27455940
22.

AOAC SMPR(®) 2016.003.

Solyom AM, Betz JM, Brown PN, Bzhelyansky A, Chrisafis N, Embuscado ME, Figore H, Johnson HE, Joseph G, Kennedy DC, Kuszak A, Mudge E, Phillips MM, Phillips T, Richards LD, Rimmer CA, Sauza B, Schaneberg BT, Skamarack J, Sullivan DM, Szpylka J, Travis J, White T, Wubben JL, Yang J, Young K, Zhou J, Coates SG.

J AOAC Int. 2016 Jul;99(4):1102-1104. doi: 10.5740/jaoacint.SMPR2016.003. No abstract available.

PMID:
27455939
23.

Time-Domain Simulation of Three Dimensional Quantum Wires.

Sullivan DM, Mossman S, Kuzyk MG.

PLoS One. 2016 Apr 28;11(4):e0153802. doi: 10.1371/journal.pone.0153802. eCollection 2016.

24.

A phase I study of indoximod in patients with advanced malignancies.

Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ.

Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216.

25.

Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.

Pisklakova A, Grigson E, Ozerova M, Chen F, Sullivan DM, Nefedova Y.

Cancer Biol Ther. 2016 May 3;17(5):477-85. doi: 10.1080/15384047.2016.1156261. Epub 2016 Mar 2.

26.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.

27.

AOAC SMPR 2015.016.

Austad J, Barrett WB, Betz JM, Burdette CQ, Don C, Erickson A, Griffiths J, Hildreth JB, Ingle P, Jennens M, Ji D, Joseph G, Kennedy DC, Kuszak A, Mudge E, Noestheden M, Phillips MM, Phinney CS, Rettinger M, Richards LD, Rimmer CA, Sarma N, Sauza B, Schaneberg BT, Solyom AM, Sullivan DM, Szpylka J, Traub J, Walters DL, Woods JP, Yang J, Yoo SJ, Zhang T, Zhang W, Zhang Y, Zhu MJ, Zielinski G, Coates SG, Zhang W, Zhang Y, Zhu MJ, Zielinski G, Coates SG.

J AOAC Int. 2016 Feb 1;99(1):320-322. doi: 10.5740/jaoac.int.SMPR2015.016. No abstract available.

PMID:
28483003
28.

AOAC SMPR 2015.015.

Ingle P, Barrett WB, Don C, Es-Safi NE, Griffiths J, Joseph G, Kennedy DC, Mudge E, Phillips MM, Richards LD, Rimmer CA, Schaneberg BT, Solyom AM, Sullivan DM, Traub J, Zhang Y, Zielinski G, Coates SG.

J AOAC Int. 2016 Feb 1;99(1):318-319. doi: 10.5740/jaoac.int.SMPR2015.015. No abstract available.

PMID:
28483002
29.

AOAC SMPR 2015.014.

Zhang Y, Betz JM, Griffiths J, Hildreth JB, Jennens M, Ji D, Joseph G, Kennedy DC, Mudge E, Ofitserova M, Phillips MM, Phillips T, Richards LD, Rimmer CA, Royce S, Schaneberg BT, Solyom AM, Sullivan DM, Szpylka J, Traub J, Wood L, Yang J, Yoo SJ, Zhou J, Zhu J, Zielinski G, Coates SG.

J AOAC Int. 2016 Feb 1;99(1):314-317. doi: 10.5740/jaoac.int.SMPR2015.014. No abstract available.

PMID:
28483001
30.

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.

Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM.

Cancer Med. 2016 Feb;5(2):294-303. doi: 10.1002/cam4.598. Epub 2015 Dec 29.

31.

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.

Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR.

Sci Rep. 2015 Nov 25;5:16991. doi: 10.1038/srep16991.

32.

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ.

Clin Cancer Res. 2015 Nov 15;21(22):5057-63. doi: 10.1158/1078-0432.CCR-15-0035.

34.

Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.

Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A.

Am J Clin Oncol. 2018 Feb;41(2):133-139. doi: 10.1097/COC.0000000000000242.

PMID:
26523441
35.

Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.

Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM.

Cancer Control. 2015 Apr;22(2):235-41.

PMID:
26068771
36.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A.

Mol Cancer Ther. 2015 Jul;14(7):1570-81. doi: 10.1158/1535-7163.MCT-15-0104. Epub 2015 May 1.

37.

Evaluation Protocol for Review of Method Validation Data by the AOAC Stakeholder Panel on Infant Formula and Adult Nutritionals Expert Review Panel.

Gill BD, Indyk HE, Blake CJ, Konings EJ, Jacobs WA, Sullivan DM.

J AOAC Int. 2015 Jan-Feb;98(1):112-5. doi: 10.5740/jaoacint.14-158.

PMID:
25857887
38.

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.

Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM, Nefedova Y.

PLoS One. 2015 Jan 30;10(1):e0117693. doi: 10.1371/journal.pone.0117693. eCollection 2015.

39.

Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico.

Appleyard CB, Antonia SJ, Sullivan DM, Santiago-Cardona PG, Cáceres W, Velez H, Torres-Ruiz JA, Wright KL.

Rev Recent Clin Trials. 2014;9(4):254-62. Review.

40.

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH.

Clin Cancer Res. 2015 Apr 1;21(7):1574-82. doi: 10.1158/1078-0432.CCR-14-2565. Epub 2015 Jan 14.

41.

The cutaneous microbiome in outpatients presenting with acute skin abscesses.

Horton JM, Gao Z, Sullivan DM, Shopsin B, Perez-Perez GI, Blaser MJ.

J Infect Dis. 2015 Jun 15;211(12):1895-904. doi: 10.1093/infdis/jiv003. Epub 2015 Jan 12.

42.

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.

Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S.

Oncotarget. 2014 Sep 30;5(18):8136-46.

43.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497. Epub 2014 Oct 7.

44.

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW.

Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078-0432.CCR-14-0868. Epub 2014 Sep 19.

45.

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM.

Semin Cancer Biol. 2014 Aug;27:62-73. doi: 10.1016/j.semcancer.2014.03.001. Epub 2014 Mar 12. Review.

46.

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.

J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.

47.

Rapid screening of novel agents for combination therapy in sarcomas.

Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR.

Sarcoma. 2013;2013:365723. doi: 10.1155/2013/365723. Epub 2013 Oct 24.

48.

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS.

Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577.

49.

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.

J Cancer. 2013 Sep 10;4(8):614-25. doi: 10.7150/jca.7080. eCollection 2013.

50.

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M.

Am J Hematol. 2014 Jan;89(1):62-7. doi: 10.1002/ajh.23587.

Supplemental Content

Loading ...
Support Center